FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB A	PPR	OVAL
-------	-----	------

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

ALSTODT LANCE			2. Issuer Name and Ticker or Trading Symbol BioRestorative Therapies, Inc. [ BRTX ]		onship of Reporting Person(s) all applicable) Director Officer (give title below)	to Issuer  10% Owner  Other (specify below)	
		` '	3. Date of Earliest Transaction (Month/Day/Year) 03/25/2019		EVP and Chief Strateg	y Officer	
(Street)  MELVILLE NY 11747  (City) (State) (Zip)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individ	vidual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person		

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)			4,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Securities Beneficially Owned	or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	3 and 4)		(111301. 4)	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		Derivative		Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		
Stock Option	\$1.42	03/25/2019		D			500,000	(1)	10/15/2028	Common Stock	500,000	(2)	0	D	
Stock Option	\$0.75	03/25/2019		A		500,000		(1)	10/15/2028	Common Stock	500,000	(2)	500,000	D	

### Explanation of Responses:

- 1. The option vests to the extent of 100,000 shares as of October 15, 2018, 150,000 shares upon the earlier of October 15, 2019 or the date on which the initial patient recruitment for the Company's Phase II lumbar clinical trial occurs, and 250,000 shares as of October 15, 2020.
- 2. The reported transaction involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price.

/s/ Lance Alstodt

03/25/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.